Start the conversation
Jara Herron, the owner of a salon and day spa in Tulsa, Okla., had just given birth to her seventh child about six years ago when she suddenly felt her chest getting tighter.
When she got to the hospital, Herron learned she was having a heart attack. Her organs soon began to fail, so doctors put her into a medical coma.
Because Herron was not a candidate for a heart transplant, her doctors instead turned to the world's smallest heart pump, one that can be inserted with a noninvasive catheter. That heart pump saved Herron's life.
And it's done the same thing for thousands of other patients around the United States.
But that's far from the only thing this innovative heart pump has done.
It's also helped hand investors 569% gains.
Its maker is a cutting-edge medtech firm with deep expertise with heart patients.
Those big gains are just a start for this life sciences leader.
In fact, it's set to double your money in as little as two years…
The Red Sox Factor
To get a sense of this firm's impact on heart patients, consider Boston's Fenway Park. That storied facility seats 37,673 people.
The sophisticated heart pumps from Abiomed Inc. (Nasdaq: ABMD) – including the Impella pump that saved Jara Herron – have saved more lives than that in recent years.
Abiomed's technicians designed the heart pumps for percutaneous coronary intervention (PCI, formerly known as angioplasty with stent) procedures. Using a long tube, doctors insert one of the pumps into a vein near the groin, and then run it up to the heart.
After that, the tiny motorized device begins to pump the blood properly. Surgeons use the device to stabilize patients after a heart attack or a high-risk procedure such as open-heart surgery.
Once it starts stimulating blood flow, the Impella pump gives the heart a chance to rest and recover while doctors continue helping the patient recover. Depending on the model in question, the Impella can remain in the body for up to six days.
This is nothing short of vital lifesaving gear. According to the Centers for Disease Control and Prevention, 610,000 Americans die from heart disease each year.
Thus, we know Abiomed has a great product that addresses a massive market.
That's great from a healthcare and technology point of view.
But what we're here for is the moneymaking perspective.
I already told you I believe Abiomed can double our money in the two years.
To see how that's going to happen, let's run it through the five "filters" of Your Tech Wealth Blueprint…
Tech Wealth Rule No. 1: Great Companies Have Great Operations
These are well-run firms with top-notch leaders.
Armed with an engineering management degree from the U.S. Military Academy at West Point, CEO Michael R. Minogue served as an infantry officer in the First Gulf War and was awarded a Bronze Star.
Minogue joined Abiomed in 2004 after serving in several management posts at GE Healthcare, one of the world's largest medtech operations. Beyond luring several members of his senior exec team from his alma mater, his chief medical officer formerly served as a cardiac care advisor to the U.S. Food and Drug Administration.
Under Minogue, Abiomed has grown sales roughly 1,800%. Just in the past five years, he has added 569% in shareholder returns. The firm boasts 22% operating margins and a 16% return on equity. It has nearly $251 million in cash on hand and almost no debt.
Tech Wealth Rule No. 2: Separate the Signals from the Noise
To create real wealth, you have to ignore the hype and find companies with rock-solid fundamentals.
This is no hype machine. Instead, every aspect of Abiomed's outreach is geared toward heart patients and improving their lives. This soft-sell approach, along with success stories, creates word-of-mouth marketing among patients and their doctors.
During the election last fall, the stock came under pressure along with the rest of the healthcare sector on fears that life sciences firms would be out of favor in Washington.
But the firm has the right products in place to profit no matter the politics of the moment. On June 9, 19 patients who used its products went to Congress to brief a panel on how Abiomed's pumps had saved their lives.
Tech Wealth Rule No. 3: Ride the Unstoppable Trends
We look for stocks in red-hot sectors because they offer the best chance for life-changing gains.
Abiomed is targeting a major trend that will last for at least the next 15 years: the aging of the 76.5 million U.S. baby boomers. Also, heart disease is on the rise along with obesity rates.
According to the CDC, heart disease and related conditions account for $1 out of every $6 spent on healthcare.
Based on a Forbes estimate that U.S. medical spending totals more than $3.8 trillion a year, Abiomed is targeting a $600 billion market packed with profit-making opportunities.
Tech Wealth Rule No. 4: Focus on Growth
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.